, is a medical oncologist and a leader in cancer product research and commercial development. He held academic positions at Harvard Medical School; the University of California, San Francisco; and the University of Oxford where he is currently an adjunct Professor. Dr. Kirn was Vice President of Clinical Research at Onyx Pharmaceuticals. After joining as the first oncology development employee, he created and initiated clinical development plans in partnership with Bayer for Nexavar, now a marketed product for kidney cancer. He also led the development of a first-in-class oncolytic virus therapeutic through to Phase III and a corporate partnership with Warner-Lambert. Onyx completed an Initial Public Offering during his tenure. Dr. Kirn subsequently consulted for Pfizer, Novartis, BiogenIdec, Schering AG and other leading oncology companies. He was an invited advisor on cancer therapy to the National Institutes of Health (U.S.), the Gene Therapy Advisory Committee (U.K.) and the European Agency for the Evaluation of Medicinal Products (E.U.). He is author of over 70 publications in peer-reviewed journals and textbooks. He founded the International Society of Oncolytic Virotherapy with Dr. Bell in 2007.
Mr. Glick is an experienced financial executive with over 25 years experience in public and private capital markets, biotechnology finance and accounting. At Genentech he was Vice President of Finance. He subsequently became Chief Financial Officer at Theravance where he led an Initial Public Offering (>$100 million raised at a post-money valuation of >$1 billion) and a major pharmaceutical partnership with GlaxoSmithKline (at least $600 million committed). He co-founded and served on the Board of Eyetech where he co-led an Initial Public Offering. Mr. Glick is co-founder and former Chairman of PEAK Surgical, Inc., a medical device company. He obtained his MBA from the Kellogg School of Business Management at Northwestern University.
Mr. Malone is an experienced financial executive with extensive experience in public and private capital markets, including the life sciences sector. He was Chief Financial Officer at publicly-traded biomedical companies including Millenium Biologix and World Heart Corporation. Mr. Malone previously held executive positions with a Swiss‑based global financial institution. Mr. Malone serves as Chairman of the Audit and Governance committees of a publicly-traded biopharmaceutical research company.
, has over 30 years of experience in biopharmaceutical development, commercialization, regulatory affairs and senior management. While at Hoffmann-La Roche he led the early-stage development of interferon-alpha (Roferon), now marketed for multiple diseases. As Vice President, Product Development at Onyx Pharmaceuticals he led the preclinical development of Nexavar in partnership with Bayer. Prior to Onyx he was Vice President at Xoma Corp. He holds a PhD in Biochemistry and an MA in Chemistry from Oxford University.
, is a leader in virology and oncolytic cancer therapeutics. He is Professor of Medicine at the University of Ottawa and the Ottawa Regional Cancer Center. He is founder of the Canadian Oncolytic Virus Consortium and the “Oncolytic Viruses as Cancer Therapeutics” conferences, as well as the International Society of Oncolytic Virotherapy. He is author of over 70 publications in peer-reviewed journals and textbooks.
.
Dr. Chaye has over 10 years of experience in business development, law, intellectual property management, technology transfer and licensing, and legal affairs. Her legal practice included providing advice on general corporate commercial matters, mergers acquisitions, and corporate finance. She represented venture capital funds in hi-tech and biotech financings. She was Business Development Manager for the Canadian Genetic Diseases Network where she directed the commercialization strategy of early stage technologies from member institutes by either forming partnerships with industry or by spinning-out new corporate entities. At MediGene, Inc. she was Director of Business Development. She led in-licensing and out-licensing of technologies for the oncolytic virus product programs, as well as the intellectual property strategies. She received her PhD in Genetics from the University of British Columbia and her Law degree from Dalhousie University.
Back to Top
